title: [Inhibition of growth hormone in insulin-dependent diabetics after oral administration of pirenzepine. Fluorophotometric study of the vitreous body].
abstract: The purpose of our study was to quantify the blood-retinal barrier permeability in five patients with insulin-dependent diabetic (mean age 14.96 +/- 2.45 years) without retinopathy, after six month with oral pirenzepine, a growth hormone inhibitor. Blood-retinal barrier permeability was determined by vitreous fluorophotometry before and after treatment with a nocturnal oral dose of pirenzepine (0.6 mg/kg the first month and 1 mg/kg the following five months). We found a significant diminution (p < 0.05) in growth hormone levels (10.48 +/- 4.94 ng/ml before treatment and 4.35 +/- 2.53 ng/ml after treatment), nevertheless, no changes in the blood-retinal barrier permeability values were observed (4.84 +/- 2.08 x 10(-6) min-1 before treatment and 4.53 +/- 2.54 x 10(-6) min-1 after treatment). We found no modifications in the levels of somatomedin C or HbA1c either. It can be concluded that oral pirenzepine used at this dose for six months, in spite of a significant decrease in growth hormone secretion, does not decrease the permeability of the blood-retinal barrier.
authors.affiliation: Département d'Ophtalmologie, Hôpital Universitaire de San-Carlos, Madrid, Espagne.
authors.forename: J M
authors.initials: JM
authors.lastname: Benitez del Castillo
authors.forename: J L
authors.initials: JL
authors.lastname: Ruibal
authors.forename: F
authors.initials: F
authors.lastname: Reverte
authors.forename: G
authors.initials: G
authors.lastname: Seara
authors.forename: P C
authors.initials: PC
authors.lastname: Fernandez
authors.forename: S
authors.initials: S
authors.lastname: Duran
authors.forename: E
authors.initials: E
authors.lastname: Casado
authors.forename: J
authors.initials: J
authors.lastname: Garcia Sanchez
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D001813:Blood-Retinal Barrier / Q000187:drug effects*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D015590:Fluorophotometry; D013006:Growth Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D008297:Male; D010890:Pirenzepine / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D010890:Pirenzepine; D013006:Growth Hormone
vernacular_title: Inhibition de l'hormone de croissance chez les sujets diabétiques insulino-dépendants après administration par voie orale de pirenzépine. Etude par fluorophotométrie du vitré.